REVANCE THERAPEUTICS, INC. SALES AGREEMENTSales Agreement • May 10th, 2022 • Revance Therapeutics, Inc. • Pharmaceutical preparations • New York
Revance Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen” or, the “Agent”), as follows:
NOTE PURCHASE AGREEMENT Dated as of March 18, 2022 among REVANCE THERAPEUTICS, INC., as the Issuer, CERTAIN SUBSIDIARIES OF THE ISSUER, as the Guarantors, ATHYRIUM BUFFALO LP, as the Administrative Agent and THE PURCHASERS FROM TIME TO TIME PARTY HERETONote Purchase Agreement • May 10th, 2022 • Revance Therapeutics, Inc. • Pharmaceutical preparations • New York
This NOTE PURCHASE AGREEMENT is entered into as of March 18, 2022 among REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Issuer”), the Guarantors (defined herein), the Purchasers (defined herein) and ATHYRIUM BUFFALO LP, as the Administrative Agent.
Re: Separation and Consulting AgreementSeparation and Consulting Agreement • May 10th, 2022 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This letter sets forth the substance of the mutual separation agreement (the “Agreement”) that Revance Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
THIRD ADDENDUM TO LICENSE AND SERVICE AGREEMENTLicense and Service Agreement • May 10th, 2022 • Revance Therapeutics, Inc. • Pharmaceutical preparations
This Third Addendum to License and Service Agreement (this “Third Addendum”) is executed as of December 9, 2021 (the “Third Addendum Date”) by and between Revance Therapeutics, Inc. (“Revance”) and List E, LLC (“List E” and together with Revance, the “Parties”).
